6DNE

Crystal structure of human Bromodomain-containing protein 4 (BRD4) bromodomain with MS660


Experimental Data Snapshot

  • Method: X-RAY DIFFRACTION
  • Resolution: 2.958 Å
  • R-Value Free: 0.285 
  • R-Value Work: 0.243 

wwPDB Validation 3D Report Full Report


This is version 1.2 of the entry. See complete history

Literature

Spatially constrained tandem bromodomain inhibition bolsters sustained repression of BRD4 transcriptional activity for TNBC cell growth.

Ren, C.Zhang, G.Han, F.Fu, S.Cao, Y.Zhang, F.Zhang, Q.Meslamani, J.Xu, Y.Ji, D.Cao, L.Zhou, Q.Cheung, K.L.Sharma, R.Babault, N.Yi, Z.Zhang, W.Walsh, M.J.Zeng, L.Zhou, M.M.

(2018) Proc. Natl. Acad. Sci. U.S.A. 115: 7949-7954

  • DOI: 10.1073/pnas.1720000115
  • Primary Citation of Related Structures:  

  • PubMed Abstract: 
  • The importance of BET protein BRD4 in gene transcription is well recognized through the study of chemical modulation of its characteristic tandem bromodomain (BrD) binding to lysine-acetylated histones and transcription factors. However, while monova ...

    The importance of BET protein BRD4 in gene transcription is well recognized through the study of chemical modulation of its characteristic tandem bromodomain (BrD) binding to lysine-acetylated histones and transcription factors. However, while monovalent inhibition of BRD4 by BET BrD inhibitors such as JQ1 blocks growth of hematopoietic cancers, it is much less effective generally in solid tumors. Here, we report a thienodiazepine-based bivalent BrD inhibitor, MS645, that affords spatially constrained tandem BrD inhibition and consequently sustained repression of BRD4 transcriptional activity in blocking proliferation of solid-tumor cells including a panel of triple-negative breast cancer (TNBC) cells. MS645 blocks BRD4 binding to transcription enhancer/mediator proteins MED1 and YY1 with potency superior to monovalent BET inhibitors, resulting in down-regulation of proinflammatory cytokines and genes for cell-cycle control and DNA damage repair that are largely unaffected by monovalent BrD inhibition. Our study suggests a therapeutic strategy to maximally control BRD4 activity for rapid growth of solid-tumor TNBC cells.


    Organizational Affiliation

    Department of Pharmacological Sciences, Icahn School of Medicine at Mount Sinai, New York, NY 10029.




Macromolecules

Find similar proteins by: Sequence  |  Structure

Entity ID: 1
MoleculeChainsSequence LengthOrganismDetails
Bromodomain-containing protein 4
A, B
434Homo sapiensMutation(s): 0 
Gene Names: BRD4 (HUNK1)
Find proteins for O60885 (Homo sapiens)
Go to Gene View: BRD4
Go to UniProtKB:  O60885
Small Molecules
Ligands 1 Unique
IDChainsName / Formula / InChI Key2D Diagram3D Interactions
H1V
Query on H1V

Download SDF File 
Download CCD File 
A
N,N'-[ethane-1,2-diylbis(oxyethane-2,1-diyl)]bis{2-[(6S)-4-(4-chlorophenyl)-2,3,9-trimethyl-6H-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepin-6-yl]acetamide}
C44 H46 Cl2 N10 O4 S2
ZKJQKCFLIQBELE-HEVIKAOCSA-N
 Ligand Interaction
Experimental Data & Validation

Experimental Data

  • Method: X-RAY DIFFRACTION
  • Resolution: 2.958 Å
  • R-Value Free: 0.285 
  • R-Value Work: 0.243 
  • Space Group: P 65 2 2
Unit Cell:
Length (Å)Angle (°)
a = 87.540α = 90.00
b = 87.540β = 90.00
c = 172.300γ = 120.00
Software Package:
Software NamePurpose
SCALAdata scaling
PHENIXrefinement
HKL-2000data reduction
BALBESphasing

Structure Validation

View Full Validation Report or Ramachandran Plots



Entry History 

Deposition Data

  • Deposited Date: 2018-06-06 
  • Released Date: 2018-07-18 
  • Deposition Author(s): Ren, C., Zhou, M.M.

Revision History 

  • Version 1.0: 2018-07-18
    Type: Initial release
  • Version 1.1: 2018-08-01
    Type: Data collection, Database references
  • Version 1.2: 2018-08-15
    Type: Data collection, Database references